Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanjing Medical UniversityNo recent work listed

Chunzhao Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7612-3491; OpenAlex author ID A5101569143. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
7
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 6

  1. Insulin promotes the proliferation and migration of pancreatic cancer cells by up-regulating the expression of PLK1 through the PI3K/AKT pathway. Last author DOI 10.1016/j.bbrc.2023.01.061↗
  2. Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy. Last author DOI 10.3389/fonc.2021.618764↗
  3. Polo-like kinase 1 is involved in apoptosis, invasion, and metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.21037/tcr-20-1019↗
  4. Girdin interaction with vimentin induces EMT and promotes the growth and metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.3892/or.2020.7615↗
  5. Girdin regulates the proliferation and apoptosis of pancreatic cancer cells via the PI3K/Akt signalling pathway. Last author DOI 10.3892/or.2018.6469↗
  6. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. Last author DOI 10.3892/or.2016.4820↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sheng Wang · 3 shared papers, 2018–2021 · strength 0.36
  2. Kaichun Wu · 2 shared papers, 2020–2023 · strength 0.35
  3. Wulin Wang · 2 shared papers, 2020–2021 · strength 0.27
  4. Hao Hui Chen · 2 shared papers, 2020–2021 · strength 0.27
  5. Yue Fu · 1 shared paper, 2023 · strength 0.24
  6. Xiang Cao · 1 shared paper, 2023 · strength 0.24
  7. Yonghuan Mao · 2 shared papers, 2016–2020 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.